Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $55.40.

Separately, Oppenheimer lowered their price target on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a report on Friday, August 14th.

Insider Buying and Selling at Pelthos Therapeutics

In other Pelthos Therapeutics news, Director Todd C. Davis bought 35,948 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average price of $27.82 per share, with a total value of $1,000,073.36. Following the completion of the purchase, the director directly owned 75,834 shares in the company, valued at $2,109,701.88. The trade was a 90.13% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last quarter, insiders have sold 1,638 shares of company stock worth $43,107. 16.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ikarian Capital LLC boosted its holdings in Pelthos Therapeutics by 309.5% during the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after purchasing an additional 193,307 shares in the last quarter. Boothbay Fund Management LLC raised its holdings in shares of Pelthos Therapeutics by 279.8% in the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after buying an additional 59,435 shares in the last quarter. J. Goldman & Co LP bought a new position in shares of Pelthos Therapeutics during the 4th quarter worth approximately $2,418,000. Cantor Fitzgerald L. P. acquired a new stake in Pelthos Therapeutics in the 4th quarter valued at $1,085,000. Finally, Diadema Partners LP boosted its stake in Pelthos Therapeutics by 138.1% in the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after buying an additional 14,502 shares in the last quarter. Institutional investors own 77.96% of the company’s stock.

Pelthos Therapeutics Stock Performance

PTHS opened at $24.73 on Friday. The stock’s 50 day simple moving average is $27.17 and its 200-day simple moving average is $25.26. The company has a current ratio of 1.98, a quick ratio of 1.31 and a debt-to-equity ratio of 3.40. The stock has a market cap of $94.72 million, a PE ratio of -1.13 and a beta of 3.10. Pelthos Therapeutics has a 1 year low of $18.19 and a 1 year high of $37.50.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its earnings results on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%.The firm had revenue of $15.60 million during the quarter. Sell-side analysts forecast that Pelthos Therapeutics will post -15.22 EPS for the current year.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).